全球組織工程市場規模、佔有率和成長分析：按材料、按用途- 產業預測（2023-2030）

Global Tissue Engineering Market Size, Share, Growth Analysis, By Material(Synthetic Material, and Biologically Derived Material), By Application(Cord blood & Cell Banking, Gynecology) - Industry Forecast 2023-2030

出版日期: 2023年09月23日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

全球組織工程市場規模預計將從 2022 年的 143.9 億美元增至 2030 年的 324.5 億美元，在預測期內（2023-2030 年）年複合成長率為 10.7%。

由於再生醫學和器官移植的進步，市場呈現顯著成長。由於器官移植需求的增加和慢性病的流行，市場正在擴大。該公司正在投資研究開發有效的組織工程解決方案，包括支架、生物材料和細胞療法，以滿足世界各地不斷成長的醫療需求。

促進因素

包括心血管疾病、整形外科疾病和器官衰竭在內的慢性疾病的增加正在為組織工程部門提供重大推動力。組織工程為組織和器官重組提供了有前途的治療方法，為患有持續性疾病的人提供了極好的替代選擇。

市場趨勢

全球組織工程產業面臨法規障礙，包括與生物工程組織和細胞應用相關的安全性、有效性和倫理考量。嚴格的法規結構和廣泛的核准程序可能會阻礙市場進步，從而限制組織工程產品和治療方法的取得。

本報告針對全球組織工程市場進行研究與分析，提供市場動態與預測、細分分析、公司簡介等。

Organogenesis Holdings Inc. (US)
Acelity LP Inc. (US)
Medtronic plc (Ireland)
Integra LifeSciences Corporation (US)
Stryker Corporation (US)
Zimmer Biomet Holdings, Inc. (US)
Baxter International Inc. (US)
Allergan plc (Ireland)
Smith & Nephew plc (UK)
Wright Medical Group NV (Netherlands)
Cook Medical Incorporated (US)
MiMedx Group, Inc. (US)
Osiris Therapeutics, Inc. (US)
Tissue Regenix Group plc (UK)
NuVasive, Inc. (US)
Cellular Dynamics International (US)
Vericel Corporation (US)
RepliCel Life Sciences Inc. (Canada)
Organovo Holdings, Inc. (US)
AlloSource (US)

簡介目錄

Product Code: SQMIG35H2087

Global Tissue Engineering Market size was valued at USD 13 Billion in 2021 and is poised to grow from USD 14.39 Billion in 2022 to USD 32.45 Billion by 2030, at a CAGR of 10.7% during the forecast period (2023-2030).

The global tissue engineering market is experiencing significant growth due to advancements in regenerative medicine and organ transplantation. This innovative field involves creating functional tissues using biocompatible materials, cells, and biochemical factors. With increasing demand for organ transplants and the rising prevalence of chronic diseases, the market is expanding. Companies are investing in research to develop effective tissue engineering solutions, including scaffolds, biomaterials, and cell therapies, to address the growing medical needs globally.

Top-down and bottom-up approaches were used to estimate and validate the size of tissue engineering and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Drivers

The uptick in chronic ailment occurrences, encompassing cardiovascular issues, orthopedic ailments, and organ insufficiencies, has significantly propelled the tissue engineering sector. Tissue engineering presents promising remedies for tissue and organ reconstruction, providing enhanced therapeutic alternatives for individuals grappling with persistent health conditions.

Restraints

Privacy and security issues emerge with the accumulation and examination of social media data, giving rise to apprehensions about data protection. The necessity for adherence to more stringent regulations and compliance protocols could present difficulties for providers of social media analytics in their task of managing and safeguarding user data.

Market Trends

The global tissue engineering industry encounters obstacles in terms of regulations encompassing the safety, effectiveness, and ethical considerations linked to the application of bioengineered tissues and cells. Stringent regulatory frameworks and extensive endorsement procedures have the potential to hinder the advancement of the market, thereby restricting the accessibility of tissue engineering offerings and treatments.